Frankfurt/Main – Össur, Nasdaq Copenhagen listed leading global provider of innovative mobility solutions, acquired all shares of privately owned Fior & Gentz, a Germany based leading European manufacturer of lower limb neuro orthotic components. Fior & Gentz develops and distributes knee and ankle orthotic joints to create innovative custom-made orthotic solutions for patients with gait impairments due to neurological conditions. The acquisition of Fior & Gentz represents an attractive opportunity for Össur to enter the fast-growing neuro orthotics market. The transaction volume amounts to around EUR 100 million plus an earn-out of up to EUR 20 million. The payment consists of cash as well as of newly issued, listed shares of Icelandic Össur hf. to the sellers of Fior & Gentz. An international CMS team led by Dr Heike Wagner and Dr Tobias Kilian advised Össur comprehensively on all legal aspects also in connection with this transaction. CMS Germany Dr Heike Wagner, Partner Dr Tobias Kilian, Of Counsel, both Lead Dr Reiner Thieme, As­so­ci­ate Nath­alie Amrhen, Associate, all Corporate / M&A Jörg Schrade, Partner Eduard Kosavtsev, Senior Associate, both Tax Dr Roland Wiring, Partner Dr Siham Hidar, Senior Associate  Noah Rodenkirchen, Associate, all Regulatory & Lifesciences Dr Stefan Lehr, Partner, Antitrust, Competition & Trade Dr Dirk Smielick, Principal Counsel, IP Prof Dr Malte Grützmacher, Partner, IT Dr Boris Alles, Partner Dela Herr, Associate, both Labor, Employment & Pensions  Dr Franz Maurer, Counsel Wiebke Westermann, Associate, both Real Estate & Public CMS Netherlands Roman Tarlavski, Part­ner Mar­cel­lina Rietvelt, Associate, both Corporate / M&A Martijn van der Bie, Partner Gieneke van Nierop, Counsel, both Corporate / Notaries CMS Norway Nicolas Jorn Brunet, Partner Tuva Svare, Associate, both Corporate / M&A Henrik Nordling, Partner, Antitrust, Competition & TradePress Con­tact presse@cms-hs. com